Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men

2021 ◽  
Author(s):  
Lu Long ◽  
Xing Liu ◽  
Lina Jin ◽  
Tracey Simon ◽  
Wenjie Ma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Bowel Movement ◽  
Laxative Use ◽  
Movement Frequency ◽  
Bowel Movement Frequency

Abstract 839: Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men

2021 ◽  
Author(s):  
Lu Long ◽  
Xing Liu ◽  
Lina Jin ◽  
Tracey Simon ◽  
Wenjie Ma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Bowel Movement ◽  
Laxative Use ◽  
Movement Frequency ◽  
Bowel Movement Frequency

scholarly journals A Prospective Study of the Effect of Bowel Movement Frequency, Constipation, and Laxative Use on Colorectal Cancer Risk

2014 ◽  
Vol 109 (10) ◽  
pp. 1640-1649 ◽  
Author(s):  
Jessica Citronberg ◽  
Elizabeth D Kantor ◽  
John D Potter ◽  
Emily White
Keyword(s):  
Colorectal Cancer ◽  
Cancer Risk ◽  
Prospective Study ◽  
Bowel Movement ◽  
Colorectal Cancer Risk ◽  
Laxative Use ◽  
Movement Frequency ◽  
Bowel Movement Frequency ◽  
A Prospective Study

scholarly journals Prospective cohort studies of bowel movement frequency and laxative use and colorectal cancer incidence in US women and men

2013 ◽  
Vol 24 (5) ◽  
pp. 1015-1024 ◽  
Author(s):  
Xuehong Zhang ◽  
Kana Wu ◽  
Eunyoung Cho ◽  
Jing Ma ◽  
Andrew T. Chan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Studies ◽  
Cancer Incidence ◽  
Prospective Cohort ◽  
Bowel Movement ◽  
Prospective Cohort Studies ◽  
Laxative Use ◽  
Movement Frequency ◽  
Bowel Movement Frequency ◽  
Colorectal Cancer Incidence

W1903 Prevalence and Factors Associated With Low Bowel Movement Frequency in Hospitalized Older Adults

2010 ◽  
Vol 138 (5) ◽  
pp. S-762-S-763
Author(s):  
Jen-Tzer Gau ◽  
Michael Finamore ◽  
Steve Walston ◽  
Victor Heh ◽  
Tzu-Cheg Kao
Keyword(s):  
Older Adults ◽  
Bowel Movement ◽  
Factors Associated ◽  
Movement Frequency ◽  
Bowel Movement Frequency ◽  
Hospitalized Older Adults

Bowel movement frequency in late-life and incidental Lewy bodies

2007 ◽  
Vol 22 (11) ◽  
pp. 1581-1586 ◽  
Author(s):  
Robert D. Abbott ◽  
G. Webster Ross ◽  
Helen Petrovitch ◽  
Caroline M. Tanner ◽  
Daron G. Davis ◽  
...  
Keyword(s):  
Bowel Movement ◽  
Lewy Bodies ◽  
Late Life ◽  
Movement Frequency ◽  
Bowel Movement Frequency

Probiotic Use Results in Normalization of Bowel Movement Frequency in IBS. Results from a Clinical Trial with the Novel Probiotic Bifidobacteria infantis 35624

2005 ◽  
Vol 100 ◽  
pp. S326
Author(s):  
E. M. Quigley ◽  
P. J. Whorwell ◽  
L. Altringer ◽  
J. Morel ◽  
L. OʼMahony ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bowel Movement ◽  
The Novel ◽  
Movement Frequency ◽  
Bowel Movement Frequency

Impact of Methadone Dose and Baseline Bowel Movement Frequency on Efficacy of Lubiprostone for Opioid-Induced Constipation

2014 ◽  
Vol 109 ◽  
pp. S532-S533 ◽  
Author(s):  
Byron Cryer ◽  
Peter Lichtlen ◽  
Martin Wang ◽  
Taryn Losch-Beridon
Keyword(s):  
Bowel Movement ◽  
Methadone Dose ◽  
Movement Frequency ◽  
Bowel Movement Frequency

Evaluation of disease-specific and functional symptom items on carcinoid tumor patients treated with telotristat ethyl.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 427-427
Author(s):  
Stacie Hudgens ◽  
Pablo Lapuerta ◽  
Lysbeth Floden
Keyword(s):  
Quality Of Life ◽  
Weight Gain ◽  
Carcinoid Syndrome ◽  
Bowel Movement ◽  
Phase Iii ◽  
Odds Ratios ◽  
European Organisation ◽  
Movement Frequency ◽  
Bowel Movement Frequency

427 Background: Within the pivotal, phase III TELESTAR trial, telotristat ethyl significantly reduced bowel movement (BM) frequency compared to placebo ( P < 0.001) (NCT01677910). Assessing patient-related outcomes can help understand the impact of changes in BM frequency on patient lives. An analysis was done to determine whether individual items on patient-reported outcome measures show relevant patterns over the course of treatment for patients with carcinoid syndrome (CS). Methods: The TELESTAR study was a phase III, double-blind, parallel-group, randomized, placebo-controlled study comparing placebo (PBO) to telotristat ethyl (TE) in 135 patients with Carcinoid Syndrome (CS). Clinical quality of life (QoL) measurements included the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer (EORTC) GI.NET21 scales. Analyses on identified individual gastrointestinal (GI) symptom and role function items were conducted using longitudinal generalized estimation equations (GEE; reference=PBO) to characterize the likelihood of a 1-grade categorical improvement (e.g., improvement by one category on the verbal response scale). Forest plots of odds ratios (OR) and associated confidence intervals (CI) on individual items are presented. Results: At week 12, the likelihood of patients experiencing a 1-grade improvement on most GI symptoms were equivalent (OR approx. 1.0). The highest odds ratios observed with TE were for improvement in diarrhea (OR=1.86, CI=0.848-4.090) and a reduction in weight bother (OR=2.95, CI=0.713-12.199), in parallel to TELESTAR results for bowel movement frequency reduction and weight gain. Interference with daily activities (IADL) and limitations in doing work demonstrated similar outcomes (IADL OR=1.63, CI=0.617,4.288; Work OR=1.97, CI=0.722,5.376). Conclusions: The overall pattern of item level change on telotristat suggested clinical relevance for bowel movement frequency reduction and weight gain, and it was consistent with symptomatic and functional benefit in CS. Clinical trial information: NCT01677910.

Sign in / Sign up

Export Citation Format

Share Document